On-mine cost guidance rose to $1,700-$1,900 per ounce sold; group capex fell to $94.3 million. Normalized production is ...

The average price was $158.2702 per share; the company bought the shares through Goldman Sachs International on the London ...

In the 712-patient ATOMIC trial, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy, versus 76% with chemotherapy alone.

In ATOMIC, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy versus 76% with chemotherapy alone; Roche is pursuing European filings.

Underwriters may buy up to 300,000 more shares under a 30-day option. Closing is expected Oct. 19; proceeds are intended for a life-sciences loan commitment.

The five-day program runs Oct. 7-11; remaining care packages will go to people in need, and NBA legends and coaches will ...

Net proceeds and existing cash are intended to complete Phase 2b and prepare for a planned Phase 3 trial of RTN-001; the IPO ...

Underwriters have a 30-day option to buy up to 1.25 million additional shares; the offering is expected to close Oct. 13, subject to customary conditions.

The Third Circuit invited U.S. views by Oct. 13; no filing had arrived as of Oct. 8. Venezuela's motion seeks time to pursue ...

Crescent plans to use proceeds for part of the cash consideration for Devon’s Eagle Ford assets acquisition, expected to close in Q4 2026 or early 2027.

Code Guardian tests isolated copies of customer code against multi-step attack scenarios; the system is in private preview ...

Recent: Retension Pharmaceuticals Announces Pricing of Initial Public Offering . Track all RTSN press releases, SEC filings, and market updates. Latest RTSN news updated today, October 8.